Emma Åkerlund’s Post

View profile for Emma Åkerlund, graphic

Scientist, PhD, Bioengineer, experienced in: High Throughput Screening, High Content Imaging, Assay Development, Organoids, Precision Cancer Medicine, Toxicology

I'm excited to share our latest publication: The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients, in npj precision oncology. This paper was part of my postdoctoral work at Karolinska Institutet/SciLifeLab in the Kallioniemi group with the supervision of Brinton Seashore-Ludlow. Here we describe the development and use of the image based drug screening platform DET3CT with a combination testing capability. This platform enables identification of effective therapies for individual patients in a clinically relevant timeframe. Our findings indicate the promising potential of the DET3CT platform, which in the future could be useful for identifying existing and emerging drugs and drug combinations for repurposing in ovarian cancer. #precisionmedicine #ovariancancer #functionalprecisionmedicine #drugscreening https://lnkd.in/eH6mzj_4

The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients - npj Precision Oncology

The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients - npj Precision Oncology

nature.com

Maria Sjöberg

Head Preclinical at CHIESI Global Rare Diseases

11mo

Grattis Emma!

Anna Lehto

Senior Customer Solutions Manager Applications at QIAGEN

11mo

Nice to see these results, congrats!

Ricardo Coelho

Post-Doc na Universitätsspital Basel (USB

11mo

Congrats Emma! Nice work!

See more comments

To view or add a comment, sign in

Explore topics